Subject: CVD risk
Subject: HDL antioxidative capacity
Subject: LDL-oxidation
Subject: rosuvastatin
Year: 2022
Type: Article
Title: Antioxidative Effects of Rosuvastatin in Low-to-Moderate Cardiovascular Risk Subjects
Author: Vavlukis, Ana
Author: Vavlukis, Marija
Author: Mladenovska, Kristina
Author: Dimovski, Aleksandar
Author: Muñoz-García, Natàlia
Author: de Santisteban Villaplana, Victoria
Author: Padro, Teresa
Author: Badimon, Lina
Abstract: Background: Although vast clinical evidence supports the oxidative CVD hypothesis, little is known on the effects of statins on LDL/HDL oxidative functionality. Therefore, the aim of this study was to evaluate the antioxidative effects of rosuvastatin by monitoring the susceptibility of LDL to oxidation and the antioxidative HDL potential in low-to-moderate CV risk subjects. Methods: 40 adult ambulatory patients (aged 53.8±10.9 years, 27 women and 13 men) were included in the study. Data was collected from patients' records, physical examination, and blood sampling. Subjects were prescribed rosuvastatin at 20mg/day. Traditional risk-factors/indicators, lipid parameters, inflammatory/immune markers, LDL susceptibility to oxidation and HDL antioxidative potential were monitored and statistically analyzed with t-test, Chi-square test, one-way ANOVA, Mann-Whitney, and Kruskal-Wallis tests. Multivariate logistic regression analyses were made. Results were considered significant when p≤0.05. Results: 67% of the patients showed lower susceptibility of LDL to oxidation after rosuvastatin treatment (p=0.03), with no significant effect on baseline LDL oxidation and lag time. All three LDL oxidative indices were seen to be dependent on the subjects' lipid profile, hemoglobin levels and the IL-1α and IL-8 pro-inflammatory marker levels. 53% of the patients showed higher HDL antioxidative capacity after treatment, but without statistical significance (p=0.07). Increased antioxidative potential of HDL with rosuvastatin treatment was more likely in males (OR=9.350; p=0.010), and subjects achieving lower post-treatment CV relative risk levels (higher CV risk reduction) (OR=0.338; p=0.027). Conclusions: This study suggests the need of a comprehensive approach when investigating oxidative stress and LDL/HDL functions, especially in low-to-moderate CVD risk subjects.
Publisher: Macedonian Academy of Sciences and Arts / Sciendo
Relation: Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)
Identifier: oai:repository.ukim.mk:20.500.12188/25319
Identifier: Vavlukis A, Vavlukis M, Mladenovska K, Dimovski A, Muñoz-García N, de Santisteban Villaplana V, Padro T, Badimon L. Antioxidative Effects of Rosuvastatin in Low-to-Moderate Cardiovascular Risk Subjects. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2022 Apr 22;43(1):65-75. doi: 10.2478/prilozi-2022-0007. PMID: 35451294.
Identifier: http://hdl.handle.net/20.500.12188/25319Identifier: 10.2478/prilozi-2022-0007
Identifier: 43
Identifier: 1
